“As the first orally administered on-demand therapy for HAE attacks, EKTERLY provides patients and physicians with an important and welcome advance in HAE treatment options,” said Anthony J. Castaldo, ...

First trial participant treated with PTM-101, an investigational thin film formulation of paclitaxel placed directly over the tumor for continuous localized ...

Research published in Science Advances indicates that CVXGA is a promising intranasal vaccine candidate that is safe, immunogenic and potentially effective ...

GENEVA, Switzerland I July 07, 2025 I Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its ...

REDWOOD CITY, CA, USA I July 7, 2025 I MapLight Therapeutics today announced the initiation of a Phase 2 study to evaluate the efficacy, safety and ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox ...

INGELHEIM, Germany I July 7, 2025 I Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate ...

SOLANA BEACH, CA, USA I July 07, 2025 I Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people ...

VIENNA, Austria / BERLIN, Germany I July 7, 2025 I HeartBeat.bio AG and biotx.ai GmbH today announced astrategic partnership to identify and validate ...

TOKYO, Japan I July 7, 2025 I Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”), and Gero PTE. LTD. (hereafter “Gero”), a Singapore-based ...

PARIS, France I July 07, 2025 I PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with ...

SHANGHAI, China I July 4, 2025 I Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing ...